2008-10-13 18:11:03 -

- CDEX Inc. Dale Jahr, Director of Investor Relations 605-399-3617 djahr@cdex-inc.com CDEX Inc. (OTCBB: CEXI) announces that last week CEO Malcolm Philips and Pascal Pouligny, VP of its Medication Safety Division, met with European distributors to build upon the progress of its international expansion of ValiMed(TM). The CDEX delegation toured European hospitals in the United Kingdom, France and

Spain, where interviews were held with hospital officials to discuss customized specifications for the Company's medication safety products. Philips and Pouligny concluded that "our international expansion plans are moving forward on all fronts, with more details to follow in the coming weeks." (For additional discussion see Mr. Philips' CEO Corner on the Investor Page of the CDEX Web Site, www.cdexinc.com.)

Philips and Pouligny met with business partner GRIFOLS International SA (BMAD: GRF) and senior managers at the Vall D'Hebron Hospital in Barcelona, Spain. GRIFOLS, a global provider of healthcare products and services, is the exclusive distributor of ValiMed in Spain, Portugal and Italy. "ValiMed is an ideal extension of the products and services we offer," said Xavier Guix, Marketing Director at Grifols. "We are pleased with our strong strategic association with CDEX, and look forward to expanding that relationship in the future."

In France, following up on the recent introduction of ValiMed at the Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires Annual Meeting in Toulouse, Philips and Pouligny held discussions with Laurent Skvortzoff and Jean-Batiste Guillot, executives at EURAF, exclusive distributor of ValiMed in France. Together they met with senior management at major hospitals in Paris. Concluding the European tour, Philips met with senior management at the Charing Cross, Hammersmith and St. Mary's hospitals in London.

"Our European tour strengthened existing business relationships while laying the foundations for new ones," Philips remarked. "CDEX currently is represented by highly regarded distributors in European and Middle Eastern countries, with the objective of advancing an authoritative presence in all major markets in these regions. We are selling ValiMed units and supplies into the domestic US and international markets. With momentum increasing, we believe ValiMed will become the standard of care for medication safety that will accelerate our movement into markets around the world. We are continuing to expand our business alliances toward that goal."

ValiMed(TM) improves patient safety by reducing medication errors, eliminating harmful counterfeits, identifying narcotic diversion and training compounding medical personnel. Within seconds ValiMed analyzes a medication's spectroscopic signature and concentration and returns a quantitative answer requiring no user interpretation.

ABOUT CDEX

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The ValiMed(TM) product line provides life-saving validation of high-risk medications and returned narcotics. The ID2(TM) product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks such as those detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

¶ ValiMed(TM) International Expansion is Moving Forward on All
Planned Fronts